Pacira outlines $745M-$770M 2026 revenue target as 5x30 strategy drives margin and pipeline progress
Source: SeekingAlpha
2026-02-26 19:58:37 ET
More on Pacira BioSciences
- Pacira BioSciences, Inc. (PCRX) Q4 2025 Earnings Call Transcript
- Pacira BioSciences: Mispriced On Generic Risks That Are Years Away
- 44th Annual J.P. Morgan Healthcare Conference
- Pacira Biosciences slips as 2026 revenue guidance, Q4 2025 results disappoint
- Pacira BioSciences Non-GAAP EPS of $0.57 misses by $0.33, revenue of $196.9M misses by $5.03M
Read the full article on Seeking Alpha
For further details see:
Pacira outlines $745M–$770M 2026 revenue target as 5x30 strategy drives margin and pipeline progress
Pacira BioSciences Inc.
NASDAQ: PCRX
PCRX Trading
2.21% G/L:
$22.01 Last:
193,033 Volume:
$21.75 Open:
PCRX Latest News
March 04, 2026 08:00:00 am
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference
March 02, 2026 08:00:00 am
Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR)
February 26, 2026 04:01:00 pm
Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results
